• Journal of the Korean Society of Laryngology, Phoniatrics and Logopedics
• /
• v.23 no.2
• /
• pp.93-98
• /
• 2012

Botulinum toxins are the most potent toxins known to mankind. Botulinum toxin acts by blocking the cholinergic neuromuscular or the cholinergic autonomic innervation of exocrine glands and smooth muscles. Seven distinct antigenic botulinum toxins (A, B, C, D, E, F and G) produced by different strains of Clostridium botulinum have been described and only A and B type of botulinum toxins were clinically used. Toxins were consisted of a heavy chain with a molecular weight of 100 kD and a light chain with a molecular weight of 50 kD. Toxins are bound with an astounding selectivity to glycoprotein structures located on the cholinergic nerve terminal. Subsequently light chain of toxin is internalized and cleaves different proteins of the acetylcholine transport protein cascade transporting the acetylcholine vesicle from the intracellular space into the synaptic cleft. After a decade of therapeutic application of the toxin, no anaphylaxis or deaths have been reported and systemic adverse effects have not been reported so far. However the toxin's immunologic properties can lead to the stimulation of antibody production, potentially rendering further treatments ineffective. Botulinum toxin is a safe and effective treatment. Use of botulinum toxin in clinical medicine has grown exponentially in recent years, and many parts of the human body are now being targeted for therapeutic purposes.

• Journal of the Korean Society of Laryngology, Phoniatrics and Logopedics
• /
• v.8 no.1
• /
• pp.65-68
• /
• 1997

The mutational falsetto is failure to change from the higher pitched voice of preadolescence to the lower pitched voice of adolescence and adulthood. The one of characteristic findings is contraction of suprahyoid muscles. The large majority of young men with inappropriately high voice have excellent voice therapy prognosis. We have experienced one case of mutational falsetto treated with botulinum toxin injection on suprahyoid muscles. His suprahyoid muscles are contracted markedly simultaneously with each phonation. fundamental frequency$(F_0)$ of his vowel phonation was 332Hz. Extensive voice therapy including manual compression of thyroid notch was ineffective. Forty units of Botox$^{\circledR}$ was injected under the EMG-guidance(20U bilaterally). At seven days post-injection, his voice changed lower than before and at 40 days after procedure, his $F_0$ was 126Hz.

• The Journal of the Korean dental association
• /
• v.41 no.6 s.409
• /
• pp.450-454
• /
• 2003

The Purpose of this study is to report the effect botulinum toxin type A injection for the masseter hypertrophy patient with bruxism. Nine patients enrolled in this study were diagnosed as masseter hypertrophy associated with bruxism and the patients were injected with a 25U of botulinum toxin type A (BTXA:Lanzhou) to each masseter muscles. All nine patients showed marked reduction of masseter hypertrophy and eight patients reported the resolution of bruxism in 8 weeks after injection, with no significant complications. This preliminary study suggest that the botulinum toxin type A injection is an alternative method to treat the masseter hypertrophy with bruxism.

• The Journal of the Korean dental association
• /
• v.48 no.12
• /
• pp.889-892
• /
• 2010

Botulinum toxin type A (BTX-A), a potent neurotoxin that reversibly blocks presynaptic acetylcholine release, has been applied successfully to treat facial spastic conditions such as blepharospasm, strabismus and cervical dystonia. Since the first reported application in dentistry in 1994, BTX-A has been used with great success to used in the orofacial region to help treat masticatory and facial muscle spasm, severe bruxism, facial tics, and hypertrophy of the masticatory muscles. The clinician may be aware of the many courses becoming available and aimed at dentists to start using it in the cosmetic context. This article intends to provide a basic understanding of the many functional uses of the drug in the orofacial region that may be relevant to everyday practice, especially in orthodontic field.

• Speech Sciences
• /
• v.3
• /
• pp.5-17
• /
• 1998

Botulinum toxin, a neurotoxin derived from Clostridia Botulinum, has been injected into the target muscle(s) for the treatment of several kinds of voice and speech disorders at the Voice Clinic, Yonsei Institute of Logopedics and Phoniatrics since December 1995. Criteria for the diagnosis and method of injection for spasmodic dysphonia, mutational dysphonia, muscle tension dysphonia, dysphonia after total laryngectomy, and stuttering were summarized. Among 144 patients with adductor type spasmodic dysphonia, who were injected one time to maximum 8 times during the 27 months, 90% were recognized as having better than slight improvement. Even though the injected cases were small, not only the abductor type spasmodic dysphonia, but also the intractable mutational dysphonia or muscle tension dysphonia resistant to voice therapy revealed that botulinum toxin injection would be another options for treatment. Patients who cannot phonate after total laryngectomy and some forms of adulthood stutterers can also be candidates for the injection of botulinum toxin.

• Journal of the Korean Society of Laryngology, Phoniatrics and Logopedics
• /
• v.8 no.2
• /
• pp.193-198
• /
• 1997

Stuttering is a movement disorder of speech-motor control characterized by inappropriate timing of lingual, labial, laryngeal, and respiratory muscles. Treatment for adult stutterers have included traditional and non-traditional behavioral and psychiatric modalities, many with good initial success but all with limited long-term benefit. Recent trials of botulinum toxin injection was somewhat favorable. In this study, the authors injected 5-8 U of botulinum toxin into the thyroarytenoid muscle bilaterally in cases of disabling stutterers. Evaluation after 4 weeks of injection, 80% of the patients was improved more than one positive scale. However, no one was improved to almostly normal range.

• Journal of Oral Medicine and Pain
• /
• v.30 no.3
• /
• pp.345-351
• /
• 2005

The purpose of this double-blind study was to evaluate clinical effects of botulinum toxin type A (BTX-A) injection on myofascial pain syndrome (MPS) involving upper trapezius and compare with those of lidocaine injection. 21 patients presenting with active TrP1 and/or TrP2 in the upper trapezius over 6 months were selected for this study. The subjects were randomly divided into two groups; one group injected with BTX-A (15 unit of $Botox^{(R)}$ / 0.3 ml per trigger point (TrP)) and the other group injected with 0.5% lidocaine (0.3 ml /TrP). The clinical effects were evaluated by VAS and PPT at baseline, 2, 4, 6 and 8 weeks after treatment. BTX-A group showed persistent decrease of VAS values and increase of PPT values following treatment. While there was no significant difference in VAS values between BTX-A and lidocaine groups (p=0.347), there was significant difference in PPT values after treatment between two groups (p=0.000). The subjects received BTX-A showed noticeable improvement in PPT values after treatment, suggesting more reliable effect of BTX-A injection compared with lidocaine injection. The results of this study support that the direct injection of BTX-A to a TrP is an effective and safe treatment for MPS involving upper trapezius.

• Journal of the Korea Institute of Military Science and Technology
• /
• v.27 no.4
• /
• pp.516-527
• /
• 2024

Rapid, early, accurate detection and identification of the various pathogenic agents associated with the development of biological weapons is critical in preventing loss of life and limiting the impact of these organisms when used against civilian or military targets. The aim of this study was to produce a system for the simple, rapid, accurate and simultaneous detection and identification of Ricin, Botulinum toxin B and Staphylococcal enterotoxin B as a proof of principle for developing field appropriate reverse transcription loop-mediated isothermal amplification systems for the accurate identification of potential biological threats. These systems were designed to facilitate the identification of potential threats even in remote or resource-limited locations.

• Korean Journal of Veterinary Research
• /
• v.48 no.2
• /
• pp.161-165
• /
• 2008

Many neurotoxigenic clostridia are found in soil. Among animals, birds are especially susceptible to botulism, perhaps because they feed on insects, invertebrate carcasses, and decayed feeds contaminated with spores of Clostridium (C.) botulinum. C. botulinum type C is mainly involved in avian botulism. In the summer of 2005, death of a mute swan (cygnus olor) living in the pond of large bird cage was found in Seoul Grand Park Zoo. The birds presented presumptive clinical signs of botulism, such as ruffled hackle feathers, abnormal posture of the head, weakness, and flaccid paralysis. At that time, pond water in the breeding facilities was drained for 7 days, but there were still remained water containing sediment of feed and feces. Therefore, botulism was suspected and an experimentation were made to detect C. botulinum in the dead mute swan. Gross post-mortem findings of a mute swan showed jelly-like hemorrhagic contents in the intestine, sands and vegetations in the stomach. C. botulinum was isolated from the liver, small intestine and large intestine samples. Botulism was also confirmed by mouse inoculation test with the organ samples. With PCR, a gene encoding C. botulinum type C toxin was detected for the several organs of the mute swan died. These results suggested that death of mute swan was caused by C. botulinum type C.

• Journal of the Korean Society of Laryngology, Phoniatrics and Logopedics
• /
• v.22 no.1
• /
• pp.52-55
• /
• 2011

Hyperfunction of the upper esophageal sphincter (UES) can cause severe dysphagia. This condition referred as cricopharyngeal dysphagia may occur after head and neck surgery due to altered muscle spasm and stenosis of the pharyngo-esophageal segment. Among various treatment options available, Botulinum toxin A (Botox) injection offers a nonsurgical treatment which is useful especially for debilitated patients, and there has been a recent increase in the clinical use of Botox by otolaryngologists for managing such conditions. A 55-year-old male with base of tongue (BOT) cancer suffered from severe dysphagia after total glossectomy and neck dissection treatment. Videofluoroscopic swallow study (VFSS) and flexible endoscopic evaluation of swallowing (FEES) showed inability to pass food through the UES due to cricopharyngeal spasm. After injection of 10 U of Bot ox into each cricopharyngeus muscles (total 20 U) via EMG-guided percutaneous injection, swallowing function had improved and oral nutrition was possible, with food passing through the UES visualized on VFSS and FEES.